A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

OBJECTIVE: Etrolizumab (rhuMAb β7, anti-β7, PRO145223) is a humanised monoclonal antibody targeting the β7 subunit of the heterodimeric integrins α4β7 and αEβ7, which are implicated in leucocyte migration and retention in ulcerative colitis (UC). This randomised phase I study evaluated the safety an...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Rutgeerts, Paul J, Fedorak, Richard N, Hommes, Daan W, Sturm, Andreas, Baumgart, Daniel C, Bressler, Brian, Schreiber, Stefan, Mansfield, John C, Williams, Marna, Tang, Meina, Visich, Jennifer, Wei, Xiaohui, Keir, Mary, Luca, Diana, Danilenko, Dimitri, Egen, Jackson, O'Byrne, Sharon
פורמט: Artigo
שפה:Inglês
יצא לאור: BMJ Group 2013
נושאים:
Inflammatory Bowel Disease
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3711369/
https://ncbi.nlm.nih.gov/pubmed/22717454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2011-301769
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים